Targeting DNA methylation for treating triple-negative breast cancer

Jia Yu, Jacqueline Zayas, Bo Qin, Liewei Wang

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


Triple-negative breast cancer (TNBC) accounts for 15-20% of all invasive breast cancers and tends to have aggressive histological features and poor clinical outcomes. Unlike, estrogen receptor- or HER2-positive diseases, TNBC patients currently lack the US FDA-approved targeted therapies. DNA methylation is a critical mechanism of epigenetic modification. It is well known that aberrant DNA methylation contributes to the malignant transformation of cells by silencing critical tumor suppressor genes. DNA methyltransferase inhibitors reactivate silenced tumor suppressor genes and result in tumor growth arrest, with therapeutic effects observed in patients with hematologic malignancies. The antitumor effect of these DNA methyltransferase inhibitors has also been explored in solid tumors, especially in TNBC that currently lacks targeted therapies.

Original languageEnglish (US)
Pages (from-to)1151-1157
Number of pages7
Issue number16
StatePublished - Nov 2019


  • DNA methylation
  • DNA methyltransferase
  • DNA methyltransferase inhibitor
  • TNBC
  • breast cancer

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology


Dive into the research topics of 'Targeting DNA methylation for treating triple-negative breast cancer'. Together they form a unique fingerprint.

Cite this